This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Study Indicates Measurement Of Estrogen Receptor By AQUA® Technology Predicts Response To Radiation Therapy In Breast Cancer

BRANFORD, Conn., Dec. 13, 2010 /PRNewswire/ -- At the San Antonio Breast Cancer Symposium held this weekend a study conducted by HistoRx Inc. and the University of Calgary was selected for discussion by the breast cancer specialists assembled for the conference.  This study of 568 patients treated at the University of Calgary had several clinically relevant conclusions:

  • Quantification of ER expression by AQUA analysis can provide a continuous recurrence risk assessment for patients being treated with tamoxifen
  • Low level ER expressing patients show significant benefit from radiation treatment whereas radiation treatment showed no benefit in high-level ER-expressing patients
  • Response to radiation treatment can be predicted by quantification of ER expression

The study was designed to assess the objectivity and reproducibility of AQUA technology across institutions and across instrument platforms, and it found that "AQUA analysis, unlike any other system for measurement of in situ protein expression, can be standardized across platforms, operators and staining runs."(1)

"There is a critical need for highly standardized and quantitative measurement of protein biomarkers in tissue specimens, particularly for estrogen receptor which is a key determinant of first-line therapy in breast cancer," stated Tony Magliocco, MD, Associate Professor in the Departments of Pathology and Laboratory Medicine and Oncology at the University of Calgary, one of the authors of the study.  "Laboratories throughout North America have discovered a significant lack of reproducibility in ER testing, and the AQUA platform may provide a solution to the problem."  

The evaluation was conducted on a cohort of retrospectively collected breast cancer specimens from patients treated with tamoxifen with or without radiotherapy.  The investigators hope to confirm the clinical findings in a second study with a prospectively assembled patient population, ideally from a cooperative group or other multi-institutional trial.  "HistoRx is pleased to see the data confirm our efforts in producing an objective, quantitative and reproducible measurement of ER in patient specimens," commented Jason Christiansen, Ph.D., Senior Director of Operations for HistoRx and another author of the paper.  "We were delighted to have the additional findings on disease recurrence and radiation response, and will follow up with the appropriate trials to confirm them."  

AQUA technology is an automated, quantitative IHC testing method that enables measurement of protein biomarkers in tissue as an aid to a pathologist's diagnosis.  AQUA analysis is used in cancer research by more than twenty leading academic centers worldwide, is part of the clinical development plans for more than ten drug candidates from major pharma companies, and has been cited in more than 90 peer-reviewed publications.  ER testing services using AQUA analysis are currently available from Genoptix Inc. (Nasdaq: GXDX), which has licensed the technology from HistoRx for this application.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs